Shire Drugs Are Next Targets Of Hedge Fund's AIA Reviews
An organization tied to hedge fund manager Kyle Bass, whose strategy of challenging drug patents in America Invents Act inter partes reviews has recently made headlines, added two Shire PLC drugs...To view the full article, register now.
Already a subscriber? Click here to view full article